Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May 28, 2025, in an 8-K filing with the Securities and Exchange Commission. The meeting saw the election of director nominees and the ratification of the company’s independent registered public accounting firm. According to InvestingPro analysis, the company faces significant financial challenges, with its stock down 87.59% over the past year.
Stockholders with shares of Class A and Class B common stock, carrying one and ten votes per share respectively, voted together on all matters. The record date for determining stockholders eligible to vote was April 2, 2025.
Director nominees Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Andrew Farquharson, Malik Nanavaty, and Lisa Rometty were elected to serve until the 2026 annual meeting. The votes cast for each director nominee were overwhelmingly in favor, with minimal withheld votes and no broker non-votes impacting the election.
Additionally, the appointment of CBIZ (NYSE:CBZ) CPAs P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with a large majority.
The filing also confirmed that Rani Therapeutics is classified as an emerging growth company as defined by the Securities Act and the Securities Exchange Act.
The 8-K filing, signed by Chief Financial Officer Svai Sanford, ensures that Rani Therapeutics continues to meet the requirements set by the Securities Exchange Act of 1934. The company’s business address is 2051 Ringwood Avenue, San Jose, California, 95131, and the business phone number is (408) 457-3700.
In other recent news, Rani Therapeutics Holdings, Inc. has announced a significant agreement with an institutional investor to issue new Series D common stock warrants, allowing the purchase of up to 13,160,172 shares at $0.65 per share. This move is expected to generate approximately $4.3 million in gross proceeds from the exercise of Series B and C warrants, which have had their exercise prices reduced to $0.65 per share. Additionally, Rani Therapeutics has entered into a research collaboration with Chugai Pharmaceutical (TADAWUL:2070) Co. to explore the use of Rani’s RaniPill® technology for delivering Chugai’s therapeutic antibodies. This partnership aims to enhance oral delivery methods for biologics, potentially replacing traditional injections.
Meanwhile, Oppenheimer has adjusted its price target for Rani Therapeutics to $4.00, down from $14.00, while maintaining an Outperform rating, following Rani’s first-quarter earnings report. The company is also facing a notice from Nasdaq regarding non-compliance with the minimum market value requirement, with a deadline of October 28, 2025, to regain compliance. In another development, Stifel analysts have maintained their Buy rating with an $8.00 price target for the company, emphasizing the potential of Rani’s RT-114 drug candidate for obesity treatment.
Rani Therapeutics continues to focus on advancing its RT-114 program, which has shown promising preclinical results, as it prepares for a Phase 1 clinical trial. The company is exploring various strategies to address the Nasdaq compliance issue, though no specific plan has been announced. These developments reflect Rani Therapeutics’ ongoing efforts to innovate in drug delivery technologies and navigate financial and regulatory challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.